Indo-Bangla PharmaceuticalsDHA:IBP 32 3-Year ROIIC % is 0.00 as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 944 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 105932.1% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Indo-Bangla Pharmaceuticals does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Indo-Bangla Pharmaceuticals 3-Year ROIIC % Related Terms
Indo-Bangla Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals 3-Year ROIIC % Chart
Indo-Bangla Pharmaceuticals Annual Data
Trend
3-Year ROIIC %
Indo-Bangla Pharmaceuticals Semi-Annual Data
3-Year ROIIC %
DHA:IBP vs : 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo-Bangla Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Indo-Bangla Pharmaceuticals's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Indo-Bangla Pharmaceuticals (DHA:IBP) has a 3-Year ROIIC % of 0.00 as of . 20. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 944 companies in the Drug Manufacturers industry.
Is Indo-Bangla Pharmaceuticals' 3-Year ROIIC % too high?
Indo-Bangla Pharmaceuticals' current 3-Year ROIIC % is 0.00. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 944 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' 3-Year ROIIC % compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 944 companies for 3-Year ROIIC %. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median 3-Year ROIIC % is 3.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current 3-Year ROIIC % is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 